Welcome to our dedicated page for Bowen Acquisition news (Ticker: BOWNU), a resource for investors and traders seeking the latest updates and insights on Bowen Acquisition stock.
Bowen Acquisition Corp (BOWNU) is a Nasdaq-listed special purpose acquisition company (SPAC) in the financial services sector, categorized as a shell company. Its public news flow centers on its capital markets activity, its proposed business combination with Shenzhen Qianzhi BioTechnology Co. Ltd., and developments related to its Nasdaq listing status and corporate governance.
News coverage for Bowen Acquisition Corp includes announcements about its initial public offering and over-allotment option, detailing the listing of its units under the symbol BOWNU and the structure of its ordinary shares and rights. Subsequent press releases describe the execution of an Agreement and Plan of Merger with Shenzhen Qianzhi BioTech and outline the planned structure of the transaction, in which a Bowen subsidiary would merge with Qianzhi Group Holding (Cayman) Limited, the parent of Qianzhi BioTech.
Investors following BOWNU-related news can also review updates on shareholder approvals and extensions of the deadline to complete a business combination, as described in the company’s proxy materials and extraordinary general meeting results. These items explain how Bowen Acquisition Corp seeks additional time to consummate its proposed business combination and how public shareholders may elect to redeem their shares in connection with such extensions.
Another key stream of news involves Nasdaq listing compliance. Bowen Acquisition Corp has reported receiving a notice of non-compliance related to the minimum number of publicly held shares, as well as a subsequent delisting determination letter citing several listing rule deficiencies. Company statements describe its intention to appeal and request a stay of suspension, while acknowledging uncertainty about the outcome. Together, these news items provide a detailed view of BOWNU’s progress toward completing its proposed merger, managing its SPAC lifecycle, and addressing stock exchange requirements.
Bowen Acquisition Corp (NASDAQ: BOWN), a special purpose acquisition company, received a delisting determination letter from Nasdaq on July 15, 2025, due to multiple listing requirement violations. The company failed to maintain: $50 million minimum market value of listed securities, 1.1 million publicly held shares, $15 million market value of publicly held shares, and 400 total shareholders.
BOWN has until July 22, 2025, to appeal the decision to a Nasdaq Hearings Panel. Without an appeal, trading will be suspended on July 24, 2025. The company intends to request a hearing and a trading suspension stay while pursuing its planned business combination with Shenzhen Qianzhi BioTechnology Co. Ltd.
Bowen Acquisition Corp (NASDAQ: BOWN) has received a non-compliance notification from NASDAQ on May 28, 2025, due to failing to submit its Q1 2025 Form 10-Q quarterly report. The company has until July 28, 2025 to submit a compliance plan to NASDAQ. If approved, NASDAQ may grant BOWN an extension of up to 180 calendar days (until November 17, 2025) to regain compliance. While this notification does not immediately affect BOWN's NASDAQ listing, there is no guarantee the company will successfully regain compliance with listing requirements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.